FAIRMOUNT FUNDS MANAGEMENT LLC
Q3 2026 Form 13-F
WEST CONSHOHOCKEN, PENNSYLVANIA
CIK 0001802528
· CRD 284844
· SEC-registered investment adviser
$1.6B Reported Value Total
FAIRMOUNT FUNDS MANAGEMENT LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $5,799,058,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $6.1B gross asset value
Hedge Fund: $5.7B · Private Equity Fund: $342.0M
Source: Form ADV filed 2026-08-07
Reported value
$1.6B
Quarter over quarter
-11.4%
Holdings
12
Top-10 concentration
97.5%
Key People
Form ADV owners & control persons
Peter Evan Harwin
MANAGING MEMBER
Tomas Kiselak
MANAGING MEMBER
Emily Florence Curtiss
GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $1.6B |
| Positions | 12 |
| Change in reported value | +5.4% |
| New positions | 2 |
| Exited positions | 2 |
| Position turnover | 28.6% |
| Top-10 concentration | 97.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
12 | $1.6B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
12 | $1.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
17 | $771.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
15 | $644.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
17 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $885.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
15 | $917.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
16 | $946.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
20 | $831.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $709.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
16 | $581.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
16 | $630.4M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
26 | $568.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
27 | $436.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
22 | $422.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
20 | $303.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 12 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ORKA ORUKA THERAPEUTICS INC | $308.6M | 19.35% |
| 2 | KRSA KORSANA BIOSCIENCES INC | $291.3M | 18.27% |
| 3 | DNTH DIANTHUS THERAPEUTICS INC | $223.4M | 14.01% |
| 4 | DMRA DAMORA THERAPEUTICS INC | $185.4M | 11.63% |
| 5 | COGT COGENT BIOSCIENCES INC | $176.2M | 11.05% |
| 6 | VRDN VIRIDIAN THERAPEUTICS INC | $104.8M | 6.57% |
| 7 | ELVN ENLIVEN THERAPEUTICS INC | $85.1M | 5.33% |
| 8 | JBIO JADE BIOSCIENCES INC | $64.0M | 4.01% |
| 9 | ZBIO ZENAS BIOPHARMA INC | $64.0M | 4.01% |
| 10 | CBIO CRESCENT BIOPHARMA INC. | $52.5M | 3.3% |
| 11 | SNSE FAETH THERAPEUTICS INC | $21.5M | 1.35% |
| 12 | IKT INHIBIKASE THERAPEUTICS INC | $17.7M | 1.11% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.